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Abstract
Three model peptides containing B-epitopes from conserved, non-repetitive regions of the merozoite surface antigens,
MSA2 and MSA1, and the erythrocyte binding protein EBP of Plasmodium falciparum were synthesised. The peptides
incorporated GPG spacers and C residues at the N and C termini, and were polymerised by oxidation to form cystine
bridges. Multiple copies of essentially the same peptide sequences were also synthesised on a branching lysyl matrix to form a
tetrameric multiple antigen peptide. Rabbits were immunised with the polymerised and multiple antigen peptides, in alum
followed by Freund’s adjuvant, and the antibody responses examined by IFA and ELISA. Reproducible antibody responses
were obtained against the MSA1 and EBP but not MSA2 peptides. IgG antibody levels detected by ELISA after three
injections of antigen in alum, increased significantly after further immunisation in Freund’s adjuvant. IgG levels were largely
maintained for at least 23 weeks after the final immunisation. IgM antibodies, generally detectable only after immunisation
in Freund’s adjuvant, were absent 23 weeks later. Antibody titres against the native protein on fixed parasites, assayed by
IFA, were three to five orders of magnitude lower than the corresponding ELISA titres against the peptides. Antibody-
dependent inhibition of P. falciparum growth in vitro could not be demonstrated with the immune rabbit sera. The MSA1
and EBP peptides elicited cross-reactive antibodies. The results suggest that the selected non-repetitive sequences are
conformationally constrained in the native proteins and only a small proportion of the anti-peptide antibodies bind to the
native proteins. The significance of the findings for the development of peptide vaccines and the use of peptides in
immunoassays is discussed. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Synthetic peptides, which are easily and inexpen-
sively produced in a pure form in bulk, can be used
to generate site speci¢c immune responses to protein
antigens [1,2]. One disadvantage of short peptides for
vaccination is that antibody formation against hap-
tenic peptides requires covalently linked sequences
that bind to class II major histocompatibility com-
plex (MHC) molecules for recognition by T-helper
(Th) cells. The ¢rst synthetic malaria peptide to
be used in a human vaccination trial was based on
the repetitive (NANP)n B-cell epitope of the Plasmo-
dium falciparum (Pf) circumsporozoite protein [3].
(NANP)3, coupled to tetanus toxoid as a carrier mol-
ecule for providing Th-epitopes, elicited repeat-spe-
ci¢c antibodies and a degree of protection against
challenge with sporozoites. Immunisation with syn-
thetic peptides containing non-repetitive B-cell epito-
pes from protective Pf merozoite surface antigens
MSA1 [4^10] and MSA2 [11^14] coupled to diphthe-
ria toxoid as a carrier in a phase I clinical trial,
showed good antibody formation [15]. However, an
unacceptable level of type III (Arthus) hypersensitiv-
ity to the toxoid was observed in the immunised in-
dividuals [15]. A disulphide-linked polymer of pepti-
des, termed SPf66, derived from MSA1 (11 aa with
the sequence YSLFQKEKMVL), the Pf circumspor-
ozoite protein repeat (NANP), and two Mr 55 and
35 kDa proteins, has been reported to protect volun-
teers against Pf malaria after immunisation in alum
[16]. SPf66 has since been widely tested in the ¢eld
but its e⁄cacy and mode of action is controversial
[17,18]. Antibodies perform a critical role in the im-
mune e¡ector mechanisms against blood stages of
the Pf. Antibodies agglutinate merozoites, block
red blood cell (rbc) recognition, cause complement
mediated lysis of merozoites, promote antibody-de-
pendent killing by neutrophils, monocyte/macro-
phages and natural killer cells, generate parasite-
toxic cytokines and nitric oxide by immune com-
plex-mediated macrophage/monocyte activation, re-
verse cytoadherence to endothelium and neutralise
parasite toxins (reviewed in [19]). Monoclonal anti-
bodies (mabs) to the 45 kDa MSA2 (alternatively
termed GYMSSA or PfMSP2) inhibit parasite
growth in culture [11^13]. Humoral immune re-
sponses to MSA2 in endemic area populations are
associated with protection against malaria [14]. Sim-
ilarly mabs against the 185^200 kDa MSA1 (alterna-
tively PMMSA or PfMSP1) inhibit parasite growth
in culture [4]. Immunisation of monkeys with MSA1
protects against Pf malaria [5^8] and antibodies in
persons living in endemic areas are associated with
protection [9,10]. A 175-kDa erythrocyte binding
protein (EBP) is a Pf merozoite receptor for glyco-
phorin A [20,21]. The EBP domain mediating the
initial binding to glycophorin has been characterised
and a 19-residue peptide located elsewhere on the
EBP molecule which reportedly elicits Pf growth in-
hibiting antibodies has been identi¢ed [22].
The repetitive sequences that constitute dominant
B-cell epitopes are found in some Pf proteins, includ-
ing MSA1 and MSA2, and may constitute a parasite
strategy for evading protective immunity (reviewed in
[19]). We therefore examined the immunogenicity of
synthetic peptides containing non-repetitive EBP,
MSA1 and MSA2 sequences as preliminary models
for developing peptide-based vaccines against the
asexual blood stages of Pf. The sequences selected
contained known B-cell epitopes that were accessible
to antibodies in immuno£uorescence assays. The two
MSA sequences also contained human T-cell epito-
pes.
The immunogenicity of peptides can often be in-
creased or sometimes induced when presented as
multiple copies in the immunogen [23,24]. Three pep-
tides, one from each antigen, were therefore synthes-
ised on a branching lysyl matrix to form tetrameric
multiple antigen peptides (MAP) [23]. Essentially the
same peptide sequences were also synthesised with
terminal GPG spacers and C-residues for homopoly-
merisation through cystine bridges. Antibody re-
sponses to the peptide constructs were then deter-
mined in rabbits.
2. Materials and methods
2.1. Peptide and MAP synthesis
Peptides were manually synthesised by standard
t-Boc solid phase chemistry using p-methyl benzhy-
drylamine resin, as modi¢ed for multiple synthesis in
polypropylene mesh bags [25]. MAPs were also syn-
thesised using t-Boc chemistry except that t-Boc-
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LAla-OCH2-phenylacetamidomethyl resin (Bachem,
Switzerland) was used to initiate synthesis and
NK,NO-Boc2-Lys (Bachem) was used for the ¢rst
and second couplings to provide the lysine sca¡old-
ing as described [23]. The e⁄ciency of every coupling
reaction was followed by a quantitative ninhydrin
procedure on an aliquot of the resin [23]. Repeated
coupling with t-Boc aa was performed where neces-
sary. On completion of synthesis, dinitrophenyl side
chain protecting groups on the histidine in MSA1
and MSA2 peptides were removed with thiophenol
[23]. Peptides and MAPs were then cleaved from
the resin by the low^high HF procedure [26]. They
were puri¢ed by reverse phase HPLC using a C18
column and a Shimadzu 8A liquid chromatograph
(Shimadzu, Japan) [27], and the aa composition
checked after hydrolysis using the Picotag system
(Waters, MA) as described [27]. The sequences of
the peptides and MAPs and the residues of the pa-
rent protein from which they were derived are shown
in Table 1.
The selection of the model non-repetitive MSA1
and MSA2 sequences was based on protein structure
prediction [28], the peptides being recognised by anti-
bodies that vary with malaria transmission rates in
endemic area populations [28], sequence conservation
in di¡erent parasite isolates, ability to induce mero-
zoite surface reactive antibodies in volunteers when
injected as diphtheria toxoid conjugates [15] and pos-
session of epitopes recognised by human T-cells in
cell proliferation assays [29,30]. The replacement of
the native C by an A in P204 and MAP104 does not
detectably a¡ect the speci¢city of the elicited anti-
bodies [15,27]. The EBP sequence was chosen for
its reported ability to induce antibodies that inhibit
Pf growth and show reactivity with merozoites in an
immuno£uorescence assay and its presence in di¡er-
ent Pf isolates except for a change in residue 1074
from D to G in the 3D7 isolate [22].
2.2. Polymerisation of peptides
Peptides P204, P209 and P230 lyophilised after
puri¢cation were dissolved in 0.01 M phosphate buf-
fered saline, pH 7.2 (PBS) at 4^10 mg ml31, the pH
adjusted to 7.6 with 0.1 M Tris/HCl and then oxi-
dised by vigorously bubbling oxygen for 6 h.
2.3. Immunisation of rabbits with peptides
Each MAP and peptide was injected into two New
Zealand white rabbits (5^7 months old) for determin-
ing immunogenicity. Rabbits received 1 mg peptide
or MAP adsorbed onto 10 mg sterile aluminium hy-
droxide gel (alum) and injected intramuscularly at
two sites. The animals were injected with antigen at
3-week intervals. Control rabbits were injected in
parallel with PBS and adjuvant in an identical man-
ner. Rabbits were ear bled before commencing im-
munisation to obtain prebleed sera (PI) and then
2 weeks after each injection of antigen. Because of
the relatively poor antibody response after three in-
jections in alum (yielding bleeds 1, 2 and 3, respec-
tively), the rabbits were further injected intramuscu-
larly with the same amounts of peptide and MAP
emulsi¢ed in Freund’s complete adjuvant (FCA) (to
give bleed 4) and subsequently twice at 3-week inter-
vals with antigen in incomplete Freund’s adjuvant
(FICA) (to give bleeds 5 and 6) and then ¢nally
with antigen in PBS (to give bleed 7). The animals
were then allowed to rest for 23 weeks without fur-
ther immunisations before bleed 8 was obtained. The
immunisation and bleeding schedule is summarised
in Fig. 1. Sera were stored at 320‡C until use. The
Table 1
Sequences of peptides and MAPs and residues of the parent protein from which they were derived
Peptide Protein (Pf isolate) Residues Sequence
P204 MSA2 (FC27) 207^223 with C in residue 221 replaced by an A [27] CGPGRNNHPQNTSDSQKEATDGPGC
P209 MSA1 (K1) 20^38 CGPGVTHESYQELVKKLEALEDAGPGC
P230 EBP (Camp) 1069^1087 CGPGNEREDERTLTKEYEDIVLKGPGC
MAP 104 MSA2 (FC27) 207^226 with C in residue 221 replaced by an A [27] RNNHPQNTSDSQKEATDGNK
MAP 109 MSA1 (K1) 20^38 VTHESYQELVKKLEALEDA
MAP 130 EBP (Camp) 1069^1087 NEREDERTLTKEYEDIVLK
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care and use of animals were according to WHO
guidelines (WHO88.1).
2.4. ELISA
ELISA was carried out on peptides P104 (se-
quence RNNHPQNTSDSQKEATDGNKC), P109
(sequence VTHESYQELVKKLEALEDAC) and
MAP130 as target antigens for the antisera to the
corresponding peptides, essentially as described pre-
viously [27]. Brie£y, polystyrene microtitre plate
wells (Costar, USA) were coated with 50 Wl of pep-
tide dissolved at 10 Wg ml31 in 0.05 M bicarbonate/
carbonate bu¡er, pH 9.6 overnight at 37‡C. The
wells were then treated with 50 Wl of methanol to
¢x the peptides and subsequently blocked for 3 h
at room temperature in 5% w/v non-fat milk powder
dissolved in PBS (Blotto). Ten-fold dilutions of rab-
bit anti-peptide sera in Blotto were used as ¢rst anti-
bodies in the ELISA. The assays were performed in
duplicate. For detecting IgM rabbit antibodies, a
peroxidase conjugated IgG fraction of a goat antise-
rum to rabbit IgM W-chains, with speci¢city for rab-
bit W-chains (ICN, USA), was used as the second
antibody. For detecting IgG rabbit antibodies, a per-
oxidase-conjugated IgG fraction of a sheep antise-
rum to rabbit IgG Fc, with speci¢city for rabbit Q-
chains (ICN, USA), was utilised as the second anti-
body. For detecting all antibody classes, a peroxi-
dase-conjugated IgG fraction of a sheep antirabbit
IgG serum with H- and L-chain speci¢city (Silenius,
Melbourne, Australia) was employed as the second
antibody. The substrates 2,2P-azino-bis (3-ethyl benz-
thiazoline-6-sulphonic acid) (ABTS) and H2O2 were
used for colour development, which was quantitated
in a Flow Multiskan Plus II ELISA reader at 405
nm. The reciprocal of the highest dilution of the
antiserum, giving an average absorbance twice that
of the corresponding preimmune serum at the same
dilution, was taken as the antibody titre.
2.5. Immuno£uorescence assay
Indirect immuno£uorescence assays (IFA) were
performed as described previously [12,13] on late
stages of 3D7 isolate Pf using a £uorescein-conju-
gated IgG fraction of sheep antirabbit IgG serum
with H- and L-chain speci¢city (Silenius, Melbourne,
Australia) as the second antibody. IFA was done at
1:25, 1:100 and 1:500 dilutions of rabbit sera as ¢rst
antibodies. Preimmune sera and sera from rabbits
immunised with PBS were used as negative controls.
A rabbit antiserum to recombinant MSA2 protein
was used as a positive control for the IFA.
2.6. Pf growth inhibition assay
[3H]Hypoxanthine incorporation growth inhibition
assays were performed as described previously [31],
except that human serum was replaced with 10% test
rabbit serum in the culture medium. All rabbit sera
were preabsorbed with human rbc before use in the
assays.
3. Results
3.1. Characterisation of polymerised peptides by
SDS-PAGE
SDS-PAGE analysis on 12.5% gels revealed that
the polymerised peptides migrated as polydisperse
material of up to Mr 24 kDa, indicating the presence
of nonamers and smaller polymers of the peptides.
3.2. Antibody response in rabbits to immunisation with
MAPs and peptide polymers
The results of ELISA to determine IgG and IgM
antibody responses to the MAPs and homopolymeric
peptides are given in Figs. 2 and 3, respectively. Sig-
ni¢cant antibody responses were detected in all rab-
bits except one (P204b) immunised with homopoly-
meric P204. Antibody responses to the MSA2
peptides (MAP104 and P204) were in general poorer
than against the other peptides. Immunisation with
antigen in alum generally yielded lower antibody
titres than after subsequent immunisations with the
peptides in Freund’s adjuvant. This was particularly
Fig. 1. Schedule of immunisation and serum collection.
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clear with IgM antibodies. The increase in antibody
titres with multiple immunisations, particularly with
the MSA1 and EBP peptides, suggests that memory
responses were generated. While IgM antibodies de-
creased to preimmune concentrations 23 weeks after
the last immunisation (bleed 8), the IgG antibody
titres were either maintained or diminished by one
order of magnitude during the same period.
When a peroxidase-conjugated sheep antibody rec-
ognising all rabbit immunoglobulin classes was used
as the second antibody in ELISA, changes in total
antibody concentrations similar to the changes in
IgG antibody concentrations were observed, except
that the titres were frequently one or two orders of
magnitude greater than the titres of IgG antibodies.
Essentially similar results were obtained when unpo-
lymerised P204 replaced P104, unpolymerised P209
replaced P109 and unpolymerised P230 replaced
MAP130 as antigens in the respective ELISAs. This
shows that basically the same epitopes are being rec-
ognised in homologous peptides.
Cross-reactions, scored when reactions with pepti-
des from a di¡erent antigen were observed at serum
dilutions greater than 1032, were signi¢cant between
Fig. 2. IgG (F) and IgM (U) rabbit antibody responses to immunisation with multiple antigen peptides (MAPs). Values of antibody
titres are expressed as logarithms to the base ten.
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the EBP and MSA1 MAPs and homopolymers.
Antisera from rabbits immunised with MAP104 or
P204 did not cross-react with the MSA1 and EBP
peptides. ELISA antibody titres observed with the
7th bleed antisera to the MSA1 and EBP peptides,
using peroxidase conjugated sheep IgG recognising
all rabbit immunoglobulin classes as a second anti-
body and P109 and unpolymerised P230 as target
antigen are shown in Table 2. The results demon-
strate that the reactions of the antisera with the im-
munising peptides were greater than the reactions
with cross-reacting peptides.
Antibody titres detected by an IFA reaction with
¢xed parasites reached a maximum with the 7th
bleed sera. However, the IFA titres were several or-
ders of magnitude lower than the ELISA titres, ex-
cept with rabbit P204b where a weak IFA reaction
was observed in the absence of detectable reaction of
the antiserum with peptide in an ELISA. The IFA
titres of the 7th bleed sera, determined with £uores-
Fig. 3. IgG (F) and IgM (U) rabbit antibody responses to immunisation with homopolymeric peptides. Values of antibody titres are
expressed as logarithms to the base ten.
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cein-conjugated antibodies that detect all rabbit im-
munoglobulin classes, are shown in Table 3.
3.3. Activity of rabbit antibodies in the Pf growth
inhibition assay
None of the antisera signi¢cantly inhibited parasite
reinvasion and growth, by microscopy or in the
[3H]hypoxanthine incorporation assay, in compari-
son to the corresponding preimmune sera and serum
from the control rabbit immunised with PBS.
4. Discussion
The potential of peptides as vaccines was ¢rst
demonstrated when peptide fragments from the to-
bacco mosaic virus were shown to inhibit precipita-
tion of the virus by an antiserum and when immuni-
sation with a hexapeptide coupled to a carrier was
shown to induce the formation of virus-neutralising
antibodies [32]. This work has now been extended to
produce neutralising antibodies against several viral
pathogens and bacterial toxins [1]. The requirement
for linked Th-epitopes that are recognised by persons
of varying MHC types is a drawback to the develop-
ment of peptide vaccines for human use. For Pf pep-
tide vaccines, this might be overcome by using Th-
epitopes from Pf proteins [33] or tetanus toxoid [34]
that are recognised in the context of many human
MHC class 2 molecules.
Polymerisation of peptides reported for SPf66 cir-
cumvents the need for a carrier for eliciting antibod-
ies [16]. This may be due to T-independent antibody
responses, the presence of uncharacterised Th-epito-
pes in the SPf66 peptide sequences or the creation of
new Th-epitopes in the polymer. Linear homopoly-
merisation of 13 and 15 aa haptenic peptides by the
carbodiimide method yielded polymers that on im-
munisation produced antibody titres of 104, a phe-
nomenon ascribed to the generation of new Th-cell
epitopes as a result of polymerisation [24]. Our re-
sults show that the MSA1 and EBP peptides can
elicit high-titre anti-peptide antibodies when pre-
sented in two di¡erent forms containing multiple
copies of the epitopes viz. MAPs or polymers linked
through cystine bridges. Similar antibody responses
to the MAPs and polymers were also observed in
mice (our unpublished observations). While there
was no prior evidence for a Th-epitope in the P230/
MAP130 EBP sequence, good IgG antibody forma-
tion and memory responses, to both homopolymeric
P230 and MAP130, suggests that an epitope recog-
nised by rabbit Th-cells is indeed present. There was
previous evidence for the presence of human T-cell
epitopes in the P209/MAP109 sequence [29,30]. The
weak rabbit antibody response to the MSA2 peptides
could involve de¢cient antigen presentation or Th-
cell recognition in rabbits, since P104-bovine serum
albumin conjugates elicit good antibody responses to
P104 in Balb/c mice [27], P104-diphtheria toxoid
Table 3
Characteristics of IFA reactions with the 7th bleed antisera on
¢xed parasites
Antiserum IFA titre IFA antigen location
MAP104a 0 ^
MAP104b 0 ^
MAP109a 25 merozoite surface
MAP109b 100 merozoite surface
MAP130a 25 merozoite
MAP130b 25 merozoite
P204a 25 merozoite surface
P204b 25 merozoite surface
P209a 100 merozoite surface
P209b 100 merozoite surface
P230a 0 ^
P230b 25 merozoite
The IFA was performed with a £uorescein-conjugated sheep
antibody that recognises all rabbit immunoglobulin classes. IFA
was carried out at serum dilutions of 1:25, 1:100 and 1:500
and the values given are the reciprocal of the highest dilution
giving a positive reaction.
Table 2
Cross-reactions between the MSA1 and EBP peptides










The 7th bleed antisera to the MSA1 and EBP peptides were
used in conjunction with a peroxidase-conjugated sheep anti-
body that detects all rabbit immunoglobulin classes. The given
values are the logarithms to the base ten of the ELISA titres.
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yielded antibodies to P104 in human volunteers and
the closely related P103 sequence was recognised by
s 60% of Solomon Islanders tested in T-cell prolif-
eration assays [30]. Hence it is possible that the hu-
man antibody responses to at least the MSA1 and
two peptides may be superior to that observed in the
rabbits. The inclusion of stronger Th-epitopes in the
peptide sequences may, however, further improve im-
munogenicity in man. Apart from intrinsic di¡eren-
ces between humans and rabbits in the immunolog-
ical repertoire, prior exposure to Pf malaria in
endemic areas would also be expected to in£uence
the human antibody response to the peptides.
Homopolymers of peptides containing B- and Th-
epitopes produced by the carbodiimide method [24]
or more recently by free radical induced polymerisa-
tion of acrolyl-derivatised peptides [35], and MAPs
[23] yield good antibody producing immunogens.
Twelve to sixteen haptenic groups are optimally re-
quired in a polymeric antigen for cross-linking B-cell
receptors and generating a type 2 T-independent
antibody response [36], which is typically dominated
by IgM antibodies. This condition is not met with
the homopolymers and MAPs used in these experi-
ments. Memory antibody responses and the prepon-
derance of IgG antibodies suggest that Th-dependent
antibody formation is a dominant feature of the ob-
served antibody responses.
Signi¢cant levels of IgG, but not IgM, antibodies
were detectable in the sera of rabbits, 23 weeks after
the ¢nal immunisation. This is consistent with the
shorter half life of IgM compared to IgG in blood.
Antibody titres after three injections in alum were
considerably lower (102 in all but rabbits MAP130a
and b, where a titre of 104 was obtained) than the
titres obtained after subsequent injections in
Freund’s adjuvant. It is possible that some of the
IgM antibodies observed after immunisation in
Freund’s adjuvant are cross-reacting IgM antibodies
produced in response to this adjuvant. The increase
in non-speci¢c antibodies, commonly observed after
immunisation in Freund’s adjuvant, may explain the
weak merozoite-surface speci¢c IFA reaction seen
with 7th bleed P204b sera in the absence of an ELI-
SA reaction with the immunising peptide. It is clear,
however. that human immunisation with peptides
will require stronger adjuvants than alum that, unlike
Freund’s, will be suitable for human use. Several
such adjuvants have recently undergone successful
clinical safety trials [37].
Reciprocal cross-reactions were signi¢cant between
the MSA1 and EBP peptides. Cross-reactions are
also seen between anti-P230 sera and P109 excluding
a role for the terminal lysine residues or the linker
sequences in generating cross-reactions. Both pepti-
des carry net negative charges at pH 7. Maximum
homology analysis of P109 and P130 showed that 10
aa matched in a 12 aa stretch as follows:
. . . . . . . V T H E S Y Q E L V K K L E A LE D A
. : . : : . . . :
:
N E R E D E R T L T K E ? Y E D I V L K . . . . . . .
The observed cross-reactivity may therefore re£ect
the importance of charge in the antibody^peptide
interaction and/or the structural homology between
the two peptides. Hence caution is needed in estimat-
ing antibody levels to native proteins by measuring
antibodies binding to immobilised peptides in ELISA
or RIA. Reactions of the di¡erent anti-peptide sera
with several Pf proteins other than parent antigen,
indicating extensive cross-reactivity, were also ob-
served in Western blots (R. Ramasamy, unpublished
observations). Extensive cross-reactions of antibodies
reacting with repetitive and non-repetitive pepide
epitopes in Pf with other Pf proteins containing
structurally related sequences have been previously
reported [38,39].
The replacement of residue 1074 G in the native
3D7 EBP protein by a D in the immunising peptide
does not prevent elicitation of antibodies reacting
with the protein by IFA. Anti-peptide ELISA titres
obtained by immunisation with MAPs and polymeric
peptides in the present study were three to ¢ve orders
of magnitude greater than the corresponding IFA
titres against merozoites. Hence only a small propor-
tion of the anti-peptide antibodies elicited by immu-
nisation with the MAPs or peptide polymers recog-
nise the conformation of the peptides in the three
native proteins. This is not desirable for human vac-
cination since formation of a large quantity of irrel-
evant antibodies may mediate pathological e¡ects.
The probable explanation for this phenomenon is
that peptides generally assume a more relaxed con-
BBADIS 61794 24-12-98
R. Ramasamy et al. / Biochimica et Biophysica Acta 1453 (1999) 115^125122
formation in solution when compared to their struc-
ture in the native protein and this in£uences the spe-
ci¢city of the antibodies elicited by the peptides [40].
Constraining peptides to resemble their conforma-
tion in the native proteins where this is known or
predictable, by using covalent bond mimics [41] or
cyclisation [42], for example, may improve the spe-
ci¢city of antibodies elicited against peptides.
Previous observations have shown that P104 and
P109 conjugated to diphtheria toxoid as a carrier and
then used to immunise volunteers in alum as an ad-
juvant, elicit anti-P104 and anti-P109 antibodies with
merozoite surface-speci¢c IFA titres, in the 640^2500
range, that were generally higher than the corre-
sponding ELISA titres against the peptides [15]. In
that study [15], identical ELISA and IFA methods to
those used here were employed, so that the di¡erence
cannot be attributed to the relative sensitivities of the
assays. Also, anti-peptide antibody titres in man to
an (NANP)3-tetanus toxoid conjugate injected in
alum were generally only one order of magnitude
greater than the IFA titres against Pf sporozoites
by IFA [43]. Anti-peptide titres to P. vivax (Pv) cir-
cumsporozoite repeats after immunisation of Saimiri
monkeys with a MAP construct in four di¡erent ad-
juvants were of the same order of magnitude as the
IFA titres against Pv sporozoites [44]. Mice immu-
nised with MAPs containing the Pf circumsporozoite
protein repeat epitope together with a Th-cell epi-
tope, in Freund’s adjuvant elicited antibodies with
similar ELISA and IFA titres [45].
One possible explanation for the di¡erent results is
that repetitive sequences in malaria parasite proteins,
which are likely to be surface located on native pro-
teins [19], assume a more similar range of conforma-
tions to the corresponding peptides in solution. Since
the repetitive sequences in malaria parasite proteins
may function in the evasion of protective immunity
[19], this could present a conundrum for peptide vac-
cine development in malaria. It is also possible that
P104 and P109 coupled to a carrier protein through
the C-terminus assume a more restricted conforma-
tion, resembling the sequence in the native proteins,
than in the corresponding MAPs or homopolymers.
The orientation of a peptide coupled to a carrier for
example is one factor that in£uences the formation
of antibodies that react with the native parent pro-
tein [46]. Another factor to be considered is that
multiple immunisations and the use of Freund’s ad-
juvant, that are features of the study reported here,
may increase the proportion of antibodies against
non-native peptide conformations. There is clearly
much that remains unknown about developing pep-
tide reagents that yield antibodies reacting with na-
tive proteins.
The P109/MAP109/P209 sequence, which consti-
tutes the N-terminus of the mature MSA1 protein,
is located 4 aa away from the 11-aa MSA1 sequence
present in the SPf66 malaria vaccine [16]. ELISA
titres of up to 25 600 are observed in persons receiv-
ing three doses of SPf66 in alum [47] but the IFA
titres against blood stage parasites are much lower,
being 160 in the ¢rst reported vaccination of man
[16]. Up to 98% inhibition of parasite growth over
a 72-h period was reported with SPf66-immune hu-
man sera [16]. The reason for the lack of inhibition
with the rabbit anti-MSA1 sera with higher ELISA
and similar IFA titres against an adjacent MSA1
sequence is therefore not clear. However, our result
is consistent with the report that only the C-terminal
19-kDa fragment of MSA1 is carried into rbc by
invading merozoites and this region of MSA1 is the
major target of invasion inhibiting antibodies [4].
While antisera raised to the 19 residue EBA peptide
conjugated to a carrier protein reportedly inhibit Pf
growth by 50% at 1:5 dilution [22], antisera pro-
duced against P230/MAP130 containing the same
peptide sequence failed to do so. It is possible that
di¡erences in the speci¢cities of the antisera are re-
sponsible for the discrepancy. Our results suggest
that inhibition of the growth of Pf asexual blood
stages may require a higher concentrations of anti-
bodies that react with native proteins than those ob-
tained by immunisation with the homopolymers and
MAPs. In addition, antibodies may need to be di-
rected towards di¡erent epitopes on the target pro-
teins. The two anti-MSA2 monoclonal antibodies
that react with a linear STNS epitope, bind to the
native protein in an IFA, and produce 90% growth
inhibition at 121^125 Wg ml31 [11], may illustrate the
type of antibody response required for inhibiting the
growth of Pf asexual blood stages. However it is
relevant to note that additional antibody-dependent
cellular mechanisms, involving monocyte/macro-
phages and neutrophils, promote the inactivation of
blood stage Pf in vivo (reviewed in [19]) and that Th1
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and cytotoxic lymphocyte responses elicited by pep-
tide immunisation against merozoites within infected
hepatocytes may also conceivably protect in vivo.
The in vitro invasion and growth inhibition assay
could therefore underestimate the vaccine potential
of the peptide constructs described here.
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